PCSK9
医学
脂肪性肝炎
可欣
脂肪肝
脂肪变性
脂肪生成
非酒精性脂肪肝
临床试验
内科学
生物信息学
胆固醇
低密度脂蛋白受体
疾病
脂质代谢
脂蛋白
生物
作者
Amir Abbas Momtazi‐Borojeni,Maciej Banach,Massimiliano Ruscica,Amirhossein Sahebkar
标识
DOI:10.1080/17512433.2022.2132229
摘要
Introduction There are inconsistent findings regarding the effect of lipid-lowering agents on nonalcoholic fatty liver disease (NAFLD). Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is an important player in cholesterol homeostasis and intracellular lipogenesis, and PCSK9 inhibitors (PCSK9-i) have been found to be efficient for pharmacological management of hyperlipidemia.Areas covered Whether PCSK9 (itself) or PCSK9-i affects NAFLD is still disputed. To address this question, we review published preclinical and clinical studies providing evidence for the role of PCSK9 in and the effect of PCSK9-I on the development and pathogenesis of NAFLD.Expert opinion The current evidence from a landscape of preclinical and clinical studies examining the role of PCSK9 in NAFLD shows controversial results. Preclinical studies indicate that PCSK9 associates with NAFLD and nonalcoholic steatohepatitis (NASH) progression in opposite directions. In humans, it has been concluded that the severity of hepatic steatosis affects the correlation between circulating PCSK9 and liver fat content in humans, with a possible impact of circulating PCSK9 in the early stages of NAFLD, but not in the late stages. However, data from clinical trials with PCSK9-i reassure to the safety of these agents, although real-life long-term evidence is needed.
科研通智能强力驱动
Strongly Powered by AbleSci AI